🤯 Have you seen our AI stock pickers’ 2024 results? 84.62%! Grab November’s list now.Pick Stocks with AI

Procter & Gamble Falls in Pre-Market, Starbucks, Tesla, PayPal Gain

Published 07/09/2018, 08:41 AM
© Reuters.  Procter & Gamble Falls in pre-market, Starbucks, Tesla, PayPal gain
SBUX
-
TMO
-
PG
-
TSLA
-
PLUR
-
CTIC
-
HELE
-
TOL
-
GRPN
-
BNTC
-
BABA
-
SIOX
-
PYPL
-

Investing.com - Stocks in focus in pre-market trade Monday:

Procter & Gamble (PG) stock fell 0.6% by 8:44 AM ET (12:44 GMT) after Jefferies downgraded the company to hold from buy based on a number of headwinds.

Starbucks (SBUX) stock traded up 0.76% as outgoing executive chairman Howard Schultz dismissed worries about slowdown in sales in China as a short-term issue. Schultz also hinted at the possibility of a tie-up with Alibaba (BABA) to accelerate online sales in the region, according to a Reuters report.

Tesla (TSLA) stock rose 0.97% as the firm increased prices of its Model S and Model X in China by $22,680-$37,800 (150,000-250,000 yuan) as a result of recently applied tariffs in the trade war between the U.S. and China.

PayPal (PYPL) stock gained 0.77% after chief executive Dan Schulman indicated that the firm’s healthy balance sheet would allow it to invest between $1 billion and $3 billion a year in acquisitions. According to an interview in Handelsblatt, Schulman also said they wouldn’t rule out a bigger deal if it were a strategic fit.

Groupon (GRPN) stock soared 10.78% after Recode reported that the firm was searching for a buyer.

Toll Brothers (TOL) stock rose 3.19% after Barron’s published an upbeat article on the firm, suggesting that it “appears to be significantly undervalued.” The story reproduced positive comments from RBC analyst Michael Dahl who has a price target of $46 on the stock and comments from chief executive Douglas Yearly who insisted there is a “disconnect between our business and the share price,” pointing to the drop from $52 at the beginning of the year to the current $37.

Helen of Troy (HELE) soared 16.73% after reporting an adjusted diluted earnings per share of $1.87, compared to consensus expectations for $1.46.

CTi Biopharma (CTIC) stock tumbled 16.923% after the firm said that the Phase 3 trial of its treatment for aggressive B-cell non-Hodgkin lymphoma did not meet its endpoint.

Pluristem (PSTI) stock gains 3.146% after the company entered a strategic collaboration with Thermo Fisher Scientific (TMO) “to advance fundamental knowledge of cell therapy industrialization and to improve quality control of the end-to-end supply chain.”

Benitec Biopharma (BNTC) stock skyrockets 124.5% after the firm announced a licensing agreement for its treatment of oculopharyngeal muscular dystrophy as well as a “broad platform collaboration with Axovant Sciences (AXON)." Shares in Axovant soared 16.4%.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.